Shots:
- Sana has reported 14mos. follow-up data from a FIH study of UP421, a hypoimmune-engineered allogeneic islet cell therapy, transplanted into a patient with Type 1 Diabetes without immunosuppression
- Results showed sustained survival & function of pancreatic β cells. At 14mos., fasting & MMTT C-peptide levels matched the first 6mos. & exceeded in mos. 9-12, with improved glycemic control between mos. 12-14; PET-MRI confirmed transplanted cells at 52wks.
- UP421 uses Sana’s Hypoimmune Platform to enable immune evasion of transplanted cells, while the company plans to advance SC451, a stem cell-derived HIP-modified islet therapy, into P-I trial following an IND filing expected in 2026
Ref: Sana Biotechnology | Image: Sana Biotechnology |Press Release
Related News: MannKind Reports Initiation of P-II (INHALE-1st) Trial of Afrezza in Pediatric Patients with Newly-Diagnosed Type 1 Diabetes
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
